Glenmark launches offer to raise up to $200 million
Glenmark Pharmaceuticals today launched an offer on the Singapore Stock Exchange to raise up to $200 million (over Rs 1,340 crore) through issue of securities.31-05-2016
31-05-2016
Glenmark Pharmaceuticals Limited (Company) announces the launch of a proposed issue of Resettable Onward Starting Equity-linked Securities due 2022 (FCCBs)
Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on October 29, 2015 and the shareholders of the Company by way of a special resolution passed by way of Postal Ballot at the deemed Extra-Ordinary General Meeting held on January 25, 2016 approved raising of funds up to USD 500 million through issuance of securities including equity shares or equity linked securities, including through QIPs,...31-05-2016
Buy Glenmark, target Rs 914: AK Prabhakar
Glenmark is a low beta stock (0.27) and is trading well above its 50-day, 100-day and 200-day moving averages at Rs 822.11, Rs 802.88 and Rs 882, respectively30-05-2016
Glenmark launches digital inhaler for asthma, obstructive pulmonary disease
Glenmark planning to launch more drugs to support Digihaler in coming months25-05-2016
Glenmark gets final nod by USFDA to sell Rufinamide drug
Rufinamide is used to treat seizures caused by Lennox-Gastaut syndrome, it will be available as tablets in 200 mg and 400 mg strengths.19-05-2016
Glenmark Pharmaceuticals receives ANDA approval for Rufinamide Tablets USP, 200 mg and 400 mg
Glenmark Pharmaceuticals Ltd has submitted to BSE a copy of Press Release dated May 19, 2016 titled 'Glenmark Pharmaceuticals receives ANDA approval for Rufinamide Tablets USP, 200 mg and 400 mg'19-05-2016
Glenmark Pharmaceuticals: A lot riding on US market in fiscal 2017
Glenmark Pharmaceuticals is preparing to launch the generic version of cholesterol-lowering drug Zetia in the US, where it will be the sole generic for six months16-05-2016
Cancellation of stock options pursuant to ESOS 2003
Glenmark Pharmaceuticals Ltd has informed BSE that the Nomination and Remuneration Committee of the Company, at its meeting held on May 12, 2016 has cancelled 27,500 stock options pursuant to ESOS 2003.12-05-2016
Allotment of equity shares on exercise of options
Glenmark Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company, at its Meeting held on May 12, 2016 allotted 8,000 equity shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.12-05-2016
Glenmark posts Rs 143 crore profit on revenue growth
Consolidated revenue rose to Rs 2,306 crore up 29% from Rs 1,775 crore on a year-on-year basis12-05-2016